On November 7, 2022 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, reported that preclinical data for CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in Boston, Massachusetts (Press release, CytomX Therapeutics, NOV 7, 2022, View Source [SID1234623236]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Interferon alpha is a clinically validated, powerful antitumor agent, but has historically been limited in its clinical use due to toxicity. CX-801, our masked interferon alpha-2b therapeutic candidate, potentially addresses this limitation through a favorable predicted therapeutic index and preferential activity in the tumor micronenvironment," said Marcia P. Belvin, Ph.D., senior vice president and head of research at CytomX Therapeutics. "At the upcoming SITC (Free SITC Whitepaper) Annual Meeting, we will report encouraging preclinical data that support the development of CX-801 based on its single agent activity as well as its enhanced activity when combined with PD-L1 blockade. We plan to explore the clinical potential of CX-801 in tumor types that have traditionally been both responsive and unresponsive to immunotherapy. We look forward to continuing to progress CX-801 towards an investigational new drug application submission in the second half of 2023."